Share
Models throughout are used for illustrative purposes only.
* In patients with hemophilia A or B with inhibitors.
For health care professionals only
The information contained on this site is intended for use only by health care professionals in the United States. Countries outside of the United States may have different regulatory requirements or medical practices than the United States. Therefore, this information may not be appropriate for use outside of the United States.
Are you a health care professional in the United States?
You will now be leaving the NovoSeven® RT website.
Models throughout are used for illustrative purposes only.
* In patients with hemophilia A or B with inhibitors.
Indications and Usage
NovoSeven® RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to FVIII or FIX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.
Important Safety Information
Please click here for NovoSeven® RT Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
NovoSeven® RT is a prescription medicine.
Novo Nordisk Inc., 100 College Road West, Princeton, New Jersey 08540 U.S.A.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
NovoSeven® is a registered trademark of Novo Nordisk Health
Care AG.
© 2010
Novo Nordisk Inc. 138503R1 January 2010
